REG - Redx Pharma plc - Form 8 (OPD) - Redx Pharma Plc
09/03/2023 11:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230309:nRSI4644Sa&default-theme=true
RNS Number : 4644S Redx Pharma plc 09 March 2023
FORM 8 (OPD)
PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Redx Pharma plc
(b) Owner or controller of interests and short positions disclosed, if N/A
different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a
trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form Redx Pharma plc
relates:
Use a separate form for each offeror/offeree
(d) Is the discloser the offeror or the offeree? Offeree
(e) Date position held: 7 March 2023
The latest practicable date prior to the disclosure
(f) In addition to the company in 1(c) above, is the discloser making Yes - Jounce Therapeutics, Inc.
disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one
class of relevant securities of the offeror or offeree named in 1(c), copy
table 2(a) or (b) (as appropriate) for each additional class of relevant
security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates
Class of relevant security: Redx Ordinary shares of £0.01 each
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 0 - 0 -
(2) Cash-settled derivatives: 0 - 0 -
(3) Stock-settled derivatives (including options) and agreements to 0 - 0 -
purchase/sell:
0 - 0 -
TOTAL:
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or financial
collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities
Class of relevant security in relation to which subscription right exists: N/A
Details, including nature of the rights concerned and relevant percentages: N/A
3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO
THE OFFER MAKING THE DISCLOSURE
Details of any interests, short positions and rights to subscribe (including
directors' and other employee options) of any person acting in concert with
the party to the offer making the disclosure:
(a) Interests held by the directors of Redx Pharma plc, their close relatives
and related trusts
Name Class Number of Shares Percentage shareholding (%)
Lisa Mary Whewell Anson Ordinary 163,183 0.04872
Jane Griffiths Ordinary 84,746 0.02530
Sarah Lucinda Gordon Wild Ordinary 1,316,587 0.39311
Peter Eric Presland Ordinary 146,225 0.04366
(b) Interests held as options or awards under the share plans of Redx Pharma
plc by the directors of Redx Pharma plc and their close relatives and related
trusts who are not exempt principal traders for the purposes of Rule 8 of the
Code
Name Share Plan No. of ordinary shares under option Date of grant Vesting date Expiry date Exercise price per share (p)
Lisa Mary Whewell Anson 2020 all employee share option scheme 1,000,000 1-Jul-20 1-Jul-21 1-Jul-30 15.5
Lisa Mary Whewell Anson 2020 all employee share option scheme 1,000,000 1-Jul-20 1-Jul-22 1-Jul-30 15.5
Lisa Mary Whewell Anson 2020 all employee share option scheme 1,000,000 1-Jul-20 1-Jul-23 1-Jul-30 15.5
Lisa Mary Whewell Anson 2020 all employee share option scheme 5,300,000 1-Jul-20 1-Jul-23 1-Jul-30 15.5
Lisa Mary Whewell Anson 2020 all employee share option scheme 451,145 2-Dec-20 2-Dec-21 2-Dec-30 56.0
Lisa Mary Whewell Anson 2020 all employee share option scheme 451,145 2-Dec-20 2-Dec-22 2-Dec-30 56.0
Lisa Mary Whewell Anson 2020 all employee share option scheme 451,144 2-Dec-20 2-Dec-23 2-Dec-30 56.0
Lisa Mary Whewell Anson 2020 all employee share option scheme 2,030,152 2-Dec-20 2-Dec-23 2-Dec-30 56.0
Lisa Mary Whewell Anson 2020 all employee share option scheme 1,000,000 19-May-22 19-May-25 19-May-32 59.0
Lisa Mary Whewell Anson 2020 all employee share option scheme 1,700,000 21-Dec-22 21-Dec-25 21-Dec-32 56.5
Peter Eric Presland 2021 Director share option plan 66,666 1-Jul-21 1-Jul-22 1-Jul-31 61.5
Peter Eric Presland 2021 Director share option plan 66,667 1-Jul-21 1-Jul-23 1-Jul-31 61.5
Peter Eric Presland 2021 Director share option plan 66,667 1-Jul-21 1-Jul-24 1-Jul-31 61.5
Bernhard Kirschbaum 2021 Director share option plan 66,666 1-Jul-21 1-Jul-22 1-Jul-31 61.5
Bernhard Kirschbaum 2021 Director share option plan 66,667 1-Jul-21 1-Jul-23 1-Jul-31 61.5
Bernhard Kirschbaum 2021 Director share option plan 66,667 1-Jul-21 1-Jul-24 1-Jul-31 61.5
Sarah Lucinda Gordon Wild 2021 Director share option plan 66,666 1-Jul-21 1-Jul-22 1-Jul-31 61.5
Sarah Lucinda Gordon Wild 2021 Director share option plan 66,667 1-Jul-21 1-Jul-23 1-Jul-31 61.5
Sarah Lucinda Gordon Wild 2021 Director share option plan 66,667 1-Jul-21 1-Jul-24 1-Jul-31 61.5
Dr. Jane Veronica Griffiths 2021 Director share option plan 133,333 28-Jan-22 28-Jan-23 28-Jan-32 81.0
Dr. Jane Veronica Griffiths 2021 Director share option plan 133,333 28-Jan-22 28-Jan-24 28-Jan-32 81.0
Dr. Jane Veronica Griffiths 2021 Director share option plan 133,334 28-Jan-22 28-Jan-25 28-Jan-32 81.0
Dr. Robert Andrew Donald Scott 2021 Director share option plan 66,666 28-Jan-22 28-Jan-23 28-Jan-32 81.0
Dr. Robert Andrew Donald Scott 2021 Director share option plan 66,667 28-Jan-22 28-Jan-24 28-Jan-32 81.0
Dr. Robert Andrew Donald Scott 2021 Director share option plan 66,667 28-Jan-22 28-Jan-25 28-Jan-32 81.0
(c) Interests and short positions held by investment managers, investment
advisers and connected advisors of Redx Pharma plc
Registered holder Class Number of Shares Percentage shareholding (%)
WG Partners LLP Ordinary 114,593 0.03422
(d) Interests held by other presumed concert parties of Redx Pharma plc
Registered holder Class Number of Shares Percentage shareholding (%)
RM Special Holdings 3, LLC Ordinary 217,880,610 65.05618
RedCo II Master Fund, L.P. Ordinary 27,461,017 8.199486
Redmile Group, LLC ("Redmile") is the investment manager of RedCo II Master
Fund, L.P.
Redmile is also the investment manager of the funds that own RM Special
Holdings 3, LLC.
(e) Rights to subscribe for new securities held by other presumed concert
parties of Redx Pharma plc
Registered holder Class of relevant security Product description Due date Principal amount outstanding Conversion price Number of Ordinary Shares on conversion
RM Special Holdings 3, LLC Ordinary Shares Convertible loan notes issued by Redx Pharma plc pursuant to the terms of the 4 August 2023 (unless extended in accordance with the terms of the NPA) £11,200,026.81 £0.155 per Ordinary Share 72,258,237
note purchase agreement dated 29 June 2020 ("NPA"), convertible into Ordinary
Shares of Redx Pharma plc
(b) Interests held as options or awards under the share plans of Redx Pharma
plc by the directors of Redx Pharma plc and their close relatives and related
trusts who are not exempt principal traders for the purposes of Rule 8 of the
Code
Name Share Plan No. of ordinary shares under option Date of grant Vesting date Expiry date Exercise price per share (p)
Lisa Mary Whewell Anson 2020 all employee share option scheme 1,000,000 1-Jul-20 1-Jul-21 1-Jul-30 15.5
Lisa Mary Whewell Anson 2020 all employee share option scheme 1,000,000 1-Jul-20 1-Jul-22 1-Jul-30 15.5
Lisa Mary Whewell Anson 2020 all employee share option scheme 1,000,000 1-Jul-20 1-Jul-23 1-Jul-30 15.5
Lisa Mary Whewell Anson 2020 all employee share option scheme 5,300,000 1-Jul-20 1-Jul-23 1-Jul-30 15.5
Lisa Mary Whewell Anson 2020 all employee share option scheme 451,145 2-Dec-20 2-Dec-21 2-Dec-30 56.0
Lisa Mary Whewell Anson 2020 all employee share option scheme 451,145 2-Dec-20 2-Dec-22 2-Dec-30 56.0
Lisa Mary Whewell Anson 2020 all employee share option scheme 451,144 2-Dec-20 2-Dec-23 2-Dec-30 56.0
Lisa Mary Whewell Anson 2020 all employee share option scheme 2,030,152 2-Dec-20 2-Dec-23 2-Dec-30 56.0
Lisa Mary Whewell Anson 2020 all employee share option scheme 1,000,000 19-May-22 19-May-25 19-May-32 59.0
Lisa Mary Whewell Anson 2020 all employee share option scheme 1,700,000 21-Dec-22 21-Dec-25 21-Dec-32 56.5
Peter Eric Presland 2021 Director share option plan 66,666 1-Jul-21 1-Jul-22 1-Jul-31 61.5
Peter Eric Presland 2021 Director share option plan 66,667 1-Jul-21 1-Jul-23 1-Jul-31 61.5
Peter Eric Presland 2021 Director share option plan 66,667 1-Jul-21 1-Jul-24 1-Jul-31 61.5
Bernhard Kirschbaum 2021 Director share option plan 66,666 1-Jul-21 1-Jul-22 1-Jul-31 61.5
Bernhard Kirschbaum 2021 Director share option plan 66,667 1-Jul-21 1-Jul-23 1-Jul-31 61.5
Bernhard Kirschbaum 2021 Director share option plan 66,667 1-Jul-21 1-Jul-24 1-Jul-31 61.5
Sarah Lucinda Gordon Wild 2021 Director share option plan 66,666 1-Jul-21 1-Jul-22 1-Jul-31 61.5
Sarah Lucinda Gordon Wild 2021 Director share option plan 66,667 1-Jul-21 1-Jul-23 1-Jul-31 61.5
Sarah Lucinda Gordon Wild 2021 Director share option plan 66,667 1-Jul-21 1-Jul-24 1-Jul-31 61.5
Dr. Jane Veronica Griffiths 2021 Director share option plan 133,333 28-Jan-22 28-Jan-23 28-Jan-32 81.0
Dr. Jane Veronica Griffiths 2021 Director share option plan 133,333 28-Jan-22 28-Jan-24 28-Jan-32 81.0
Dr. Jane Veronica Griffiths 2021 Director share option plan 133,334 28-Jan-22 28-Jan-25 28-Jan-32 81.0
Dr. Robert Andrew Donald Scott 2021 Director share option plan 66,666 28-Jan-22 28-Jan-23 28-Jan-32 81.0
Dr. Robert Andrew Donald Scott 2021 Director share option plan 66,667 28-Jan-22 28-Jan-24 28-Jan-32 81.0
Dr. Robert Andrew Donald Scott 2021 Director share option plan 66,667 28-Jan-22 28-Jan-25 28-Jan-32 81.0
(c) Interests and short positions held by investment managers, investment
advisers and connected advisors of Redx Pharma plc
Registered holder Class Number of Shares Percentage shareholding (%)
WG Partners LLP Ordinary 114,593 0.03422
(d) Interests held by other presumed concert parties of Redx Pharma plc
Registered holder Class Number of Shares Percentage shareholding (%)
RM Special Holdings 3, LLC Ordinary 217,880,610 65.05618
RedCo II Master Fund, L.P. Ordinary 27,461,017 8.199486
Redmile Group, LLC ("Redmile") is the investment manager of RedCo II Master
Fund, L.P.
Redmile is also the investment manager of the funds that own RM Special
Holdings 3, LLC.
(e) Rights to subscribe for new securities held by other presumed concert
parties of Redx Pharma plc
Registered holder Class of relevant security Product description Due date Principal amount outstanding Conversion price Number of Ordinary Shares on conversion
RM Special Holdings 3, LLC Ordinary Shares Convertible loan notes issued by Redx Pharma plc pursuant to the terms of the 4 August 2023 (unless extended in accordance with the terms of the NPA) £11,200,026.81 £0.155 per Ordinary Share 72,258,237
note purchase agreement dated 29 June 2020 ("NPA"), convertible into Ordinary
Shares of Redx Pharma plc
Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or financial
collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the party to
the offer making the disclosure or any person acting in concert with it:
Irrevocable commitments and letters of intent should not be included. If there
are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or
derivatives
Details of any agreement, arrangement or understanding, formal or informal,
between the party to the offer making the disclosure, or any person acting in
concert with it, and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant
securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) No
Supplemental Form 8 (SBL) No
Date of disclosure: 9 March 2023
Contact name: Claire Solk, Group Company Secretary
Telephone number: +44(0)1625 469900
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation
to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
(http://www.thetakeoverpanel.org.uk) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END FEEFKLFBXXLFBBXRecent news on Redx Pharma
See all newsRCS - Redx Pharma plc - Redx Reports Encouraging Zamaporvint Phase 2 Data
AnnouncementREG - AIM Redx Pharma plc - Cancellation - Redx Pharma Plc
AnnouncementREG - Redx Pharma plc - Share Purchases by a PDMR
AnnouncementREG - Redx Pharma plc - Share Purchases by PDMR’s
AnnouncementREG - Redx Pharma plc - Update on AIM Delisting
Announcement